Colbatzky; Florian

Patent Applications and Registrations

Patent applications and USPTO patent grants for Colbatzky; Florian.The latest application filed is for "dihydropteridinone compounds".

Company Profile

0.9.15

Colbatzky; Florian - Stafflagen N/A DE
Colbatzky; Florian - Stafflangen DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy Grant 8,431,585 - Singer , et al. April 30, 2	2013-04-30
Dihydropteridinone compounds Grant 8,003,786 - Hoffmann , et al. August 23, 2	2011-08-23
Use of Lck inhibitors for treatment of immunologic diseases Grant 7,989,474 - Roth , et al. August 2, 2	2011-08-02
Dihydropteridinone Compounds App 20100324288 - HOFFMANN; Matthias ; et al.	2010-12-23
Methods for treating diseases or conditions using dihydropteridinone compounds Grant 7,786,299 - Hoffmann , et al. August 31, 2	2010-08-31
Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same Grant 7,750,152 - Hoffman , et al. July 6, 2	2010-07-06
Use Of Inhibitors Of The Egfr-mediated Signal Transduction For The Treatment Of Benign Prostatic Hyperplasia (bph) / Prostatic Hypertrophy App 20100144639 - SINGER; Thomas ; et al.	2010-06-10
Use of Lck inhibitors for treatment of immunologic diseases App 20090306104 - Roth; Gerald Juergen ; et al.	2009-12-10
Use of Lck inhibitors for treatment of immunologic diseases App 20090087405 - ROTH; Gerald Juergen ; et al.	2009-04-02
Piperazinyl Compounds App 20080293944 - Hoffmann; Matthias ; et al.	2008-11-27
Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions App 20080171747 - Hoffman; Matthias ; et al.	2008-07-17
Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy App 20070099918 - Singer; Thomas ; et al.	2007-05-03
Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide Grant 7,189,743 - Hauel , et al. March 13, 2	2007-03-13
Methods for treating diseases or conditions using dihydropteridinone compounds App 20060025411 - Hoffmann; Matthias ; et al.	2006-02-02
Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carb- oxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide App 20050137233 - Hauel, Norbert ; et al.	2005-06-23
Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide Grant 6,900,229 - Hauel , et al. May 31, 2	2005-05-31
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions Grant 6,861,422 - Hoffmann , et al. March 1, 2	2005-03-01
Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions App 20050014761 - Hoffmann, Matthias ; et al.	2005-01-20
Methods of treating diseases or conditions using dihydropteridinone compounds App 20050014760 - Hoffmann, Matthias ; et al.	2005-01-20
Use of Lck inhibitors for treatment of immunologic diseases App 20040204458 - Roth, Gerald Juergen ; et al.	2004-10-14
New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions App 20040176380 - Hoffmann, Matthias ; et al.	2004-09-09
Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carb- oxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide App 20040059118 - Hauel, Norbert ; et al.	2004-03-25
Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy App 20030225079 - Singer, Thomas ; et al.	2003-12-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.